
Xerys leads €14m series-B for AlzProtect
Paris-based venture firm Xerys Gestion has led a €14m series-B funding round for AlzProtect, a biopharmaceutical company that develops drugs for the treatment of neurodegenerative diseases.
As a result of the latest funding round, Xerys is now the main financial investor in the company. Other historical investors also took part in the funding round.
With the fresh capital, AlzProtect intends to develop an oral drug for the treatment of progressive supranuclear palsy, a condition in a group of neurodegenerative diseases that include Alzheimer's disease and Parkinson's disease.
Company
Founded in 2007 and headquartered in Loos, northern France, AlzProtect develops new bioactive molecules for the treatment of neurodegenerative diseases up to the first clinical trial in patients.
It also partners with pharmaceutical companies for further development and marketing.
People
Xerys Gestion – Olivier Ossipoff (president).
AlzProtect – Laurent Dupire (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater